Security Snapshot

TransMedics Group, Inc. - Common Stock (TMDX) Institutional Ownership

CUSIP: 89377M109

13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

427

Shares (Excl. Options)

37,185,318

Price

$121.65

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock
Symbol
TMDX on Nasdaq
Shares outstanding
34,330,771
Price per share
$109.36
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
37,185,318
Total reported value
$4,524,907,686
% of total 13F portfolios
0.01%
Share change
-797,348
Value change
-$83,658,461
Number of holders
427
Price from insider filings
$109.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • TMDX - TransMedics Group, Inc. - Common Stock is tracked under CUSIP 89377M109.
  • 427 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 427 to 185 between Q4 2025 and Q1 2026.
  • Reported value moved from $4,524,907,686 to $870,999,950.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 427 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 89377M109?
CUSIP 89377M109 identifies TMDX - TransMedics Group, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of TransMedics Group, Inc. - Common Stock (TMDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +16% $467,547,574 +$64,260,663 5,058,396 +16% FMR LLC 31 Mar 2025
BlackRock, Inc. 15% $664,054,661 4,955,262 BlackRock, Inc. 30 Jun 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 5.7% $193,791,842 1,949,420 Vanguard Portfolio Management 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.1% $172,688,789 1,737,137 Vanguard Capital Management 31 Mar 2026

As of 31 Dec 2025, 427 institutional investors reported holding 37,185,318 shares of TransMedics Group, Inc. - Common Stock (TMDX). This represents 108% of the company’s total 34,330,771 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of TransMedics Group, Inc. - Common Stock (TMDX) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 16% 5,395,232 +1.2% 0.01% $656,329,974
FMR LLC 15% 5,077,036 +0.25% 0.03% $617,621,412
VANGUARD GROUP INC 11% 3,605,279 -0.01% 0.01% $438,582,190
STATE STREET CORP 3.7% 1,275,133 -0.34% 0.01% $155,119,929
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 2.9% 996,878 -6.8% 0.03% $121,270,211
GOLDMAN SACHS GROUP INC 2.8% 965,931 +37% 0.02% $117,505,506
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 2.4% 832,241 0% 0.15% $101,242,000
GEODE CAPITAL MANAGEMENT, LLC 2.4% 816,474 +0.36% 0.01% $99,339,491
Driehaus Capital Management LLC 2.1% 712,041 -3.5% 0.59% $86,619,788
Hood River Capital Management LLC 2% 690,357 +1.8% 0.92% $83,981,929
Invesco Ltd. 2% 684,574 +77% 0.01% $83,278,427
MORGAN STANLEY 1.9% 667,761 +22% 0% $81,233,295
UBS Group AG 1.9% 659,296 -23% 0.02% $80,203,359
PRICE T ROWE ASSOCIATES INC /MD/ 1.7% 569,970 +43% 0.01% $69,338,000
EVENTIDE ASSET MANAGEMENT, LLC 1.6% 548,267 +0.18% 1% $66,698,201
DIMENSIONAL FUND ADVISORS LP 1.4% 489,710 +8.6% 0.01% $59,573,649
TWO SIGMA INVESTMENTS, LP 1.3% 435,969 -31% 0.08% $53,035,629
WELLINGTON MANAGEMENT GROUP LLP 1.3% 433,321 +100% 0.01% $52,713,499
JPMORGAN CHASE & CO 1.1% 375,261 -4.4% 0% $45,650,501
TWO SIGMA ADVISERS, LP 1.1% 362,300 -14% 0.09% $44,073,795
EMERALD ADVISERS, LLC 1% 351,349 -9.3% 1.3% $42,741,606
NORTHERN TRUST CORP 0.99% 339,216 -2.4% 0.01% $41,265,627
WASATCH ADVISORS LP 0.97% 331,848 +2% 0.24% $40,369,309
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.94% 323,026 +0.7% 0.01% $39,296,113
BAILLIE GIFFORD & CO 0.92% 316,473 +21% 0.03% $38,498,941

Institutional Holders of TransMedics Group, Inc. - Common Stock (TMDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 8,754,547 $870,999,950 +$10,766,212 $99.41 185
2025 Q4 37,185,318 $4,524,907,686 -$83,658,461 $121.65 427
2025 Q3 37,129,044 $4,166,232,859 -$8,088,244 $112.20 386
2025 Q2 36,786,193 $4,927,662,357 -$289,195,543 $134.01 366
2025 Q1 39,009,472 $2,625,618,476 +$165,932,691 $67.28 295
2024 Q4 36,855,938 $2,297,784,694 -$388,696,786 $62.35 308
2024 Q3 36,492,550 $5,723,369,932 +$61,413,519 $157.00 365
2024 Q2 33,743,529 $5,082,407,329 +$90,020,373 $150.62 331
2024 Q1 34,019,976 $2,515,517,054 -$71,270,565 $73.94 251
2023 Q4 34,973,168 $2,760,564,347 -$4,091,949 $78.93 244
2023 Q3 34,944,103 $1,913,888,694 +$75,708,281 $54.75 218
2023 Q2 32,524,695 $2,731,143,204 +$226,755,585 $83.98 238
2023 Q1 29,891,511 $2,263,659,591 +$69,279,751 $75.73 221
2022 Q4 28,992,696 $1,789,417,886 +$38,499,424 $61.72 196
2022 Q3 28,283,349 $1,180,766,429 +$229,245,326 $41.74 174
2022 Q2 22,873,577 $719,448,960 +$66,828,071 $31.45 129
2022 Q1 20,846,434 $561,189,812 +$24,725,042 $26.94 107
2021 Q4 20,080,660 $384,713,814 +$27,430,654 $19.16 116
2021 Q3 19,228,003 $636,263,034 +$13,347,336 $33.09 116
2021 Q2 18,779,205 $623,049,047 +$1,144,101 $33.18 117
2021 Q1 18,628,828 $772,924,082 -$21,007,487 $41.49 104
2020 Q4 21,299,571 $423,671,614 -$4,482,122 $19.90 67
2020 Q3 20,827,226 $287,000,555 +$6,185,866 $13.78 71
2020 Q2 20,159,299 $361,233,740 +$92,950,873 $17.92 68
2020 Q1 15,072,652 $182,072,226 -$2,049,598 $12.08 53
2019 Q4 14,958,642 $284,357,755 -$13,693 $19.01 59
2019 Q3 14,301,117 $336,971,808 +$4,714,704 $23.75 49
2019 Q2 11,228,228 $311,861,739 +$311,859,996 $28.99 59
2019 Q1 54 $2,000 $37.04 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .